Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)Keshu Zhou, Jianyong Li, Tingyu Wang et al.|Blood|2025Cited by 0
Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real‐world analysis from the Chinese Myeloma CommitteeXuelin Dou, Jin Lu, Ling Qin et al.|British Journal of Haematology|2026Cited by 0